Article
Integrating angiogenesis signature and tumor mutation burden for improved patient stratification in immune checkpoint blockade therapy for muscle-invasive bladder cancer.
Urologic oncology - 1 Oct 2023
Shao Fei, Jin Kaifeng, Li Bingyu, Liu Zhaopei, Zeng Han, Wang Yiwei, Zhu Yu, Xu Le, Xu Jiejie, Wang Zewei, Chang Yuan, Zhang Weijuan
Abstract excerpt
BACKGROUND: Muscle-invasive bladder cancer (MIBC) patients have benefitted greatly from immune checkpoint blockade (ICB) therapy. However, there is a pressing need to identify factors underlying the heterogeneity of clinical responses to ICB. METHODS: We conducted a study on 848 MIBC patients from 4 independent cohorts to investigate the key biological characteristics affecting ICB responses. The IMvigor210...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.